GAITHERSBURG, Md., Aug. 6, 2025 /PRNewswire/ -- Novavax, Inc. today announced its financial results and operational highlights for the second quarter ended June 30, 2025. "This quarter we continued to ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

What Happened? Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

What Happened? Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 3% in the morning session after reports revealed that its JN.1 Covid-19 vaccine became available at some GP clinics ...

On Thursday, Novavax Inc. (NASDAQ:NVAX) reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the consensus of $343.85 million. Higher product sales for the ...

Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-reports-second-quarter-2025-financial-results-and-operational-highlights ...

Adjusted Total Revenue is a non-GAAP financial measure. Adjusted Total Revenue is total revenue excluding Sanofi Supply Sales, Sanofi Royalties and Sanofi Influenza-COVID-19 Combination and Matrix-M ...